

| Controlled substance                              | Drug code | Schedule |
|---|-----------|----------|
| Dihydrocodeine .....                              | 9120      | II       |
| Difenoxin .....                                   | 9168      | I        |
| Diphenoxylate .....                               | 9170      | II       |
| Heroin .....                                      | 9200      | I        |
| Levomethorphan .....                              | 9210      | II       |
| Levorphanol .....                                 | 9220      | II       |
| Meperidine .....                                  | 9230      | II       |
| Dextropropoxyphene, bulk (non-dosage forms) ..... | 9273      | II       |
| Morphine-N-oxide .....                            | 9307      | I        |
| Thebaine .....                                    | 9333      | II       |
| Norlevorphanol .....                              | 9634      | I        |
| Oxymorphone .....                                 | 9652      | II       |
| Noroxymorphone .....                              | 9668      | II       |
| Alfentanil .....                                  | 9737      | II       |
| Sufentanil .....                                  | 9740      | II       |

The company plans to import the bulk control substances for distribution of analytical reference standards to its customers for analytical testing of raw materials.

**William T. McDermott,**  
Assistant Administrator.

[FR Doc. 2020-08269 Filed 4-17-20; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-624]

**Importer of Controlled Substances  
Application: VHG Labs DBA LGC  
Standards**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 20, 2020. Such persons may also file a written request for a hearing on the application on or before May 20, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn:

Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on March 12, 2020, VHG Labs DBA LGC Standards, 3 Perimeter Road, Manchester, New Hampshire 03103, applied to be registered as an importer of the following basic class(es) of controlled substances:

| Controlled substance   | Drug code | Schedule |
|--|-----------|----------|
| Cathinone .....  | 1235      | I        |
| Methcathinone .....  | 1237      | I        |
| Naphyrone .....  | 1258      | I        |
| N-Ethylamphetamine .....   | 1475      | I        |
| JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .....                              | 6250      | I        |
| SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ..... | 7008      | I        |
| APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .....             | 7048      | I        |
| JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) .....                              | 7081      | I        |
| SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole) .....            | 7104      | I        |
| JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .....                   | 7118      | I        |
| JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) .....                               | 7122      | I        |
| UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .....         | 7144      | I        |
| JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) .....                               | 7203      | I        |
| lbogaine .....   | 7260      | I        |
| Lysergic acid diethylamide .....   | 7315      | I        |
| Marihuana Extract .....  | 7350      | I        |
| Marihuana .....  | 7360      | I        |
| Tetrahydrocannabinols .....  | 7370      | I        |
| Mescaline .....  | 7381      | I        |
| JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) .....                               | 7398      | I        |
| 3,4-Methylenedioxyamphetamine .....  | 7405      | I        |
| 5-Methoxy-N-N-dimethyltryptamine .....   | 7431      | I        |
| Psilocyn .....   | 7438      | I        |
| 4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP) .....                                | 7498      | I        |
| MDPV (3,4-Methylenedioxypropylvalerone) .....  | 7535      | I        |
| Methylone (3,4-Methylenedioxy-N-methylcathinone) .....                                 | 7540      | I        |
| Butylone .....   | 7541      | I        |
| Pentylone .....  | 7542      | I        |
| Codeine-N-oxide .....  | 9053      | I        |

| Controlled substance  | Drug code | Schedule |
|---|-----------|----------|
| Desomorphine .....  | 9055      | I        |
| Dihydromorphine .....   | 9145      | I        |
| Heroin .....  | 9200      | I        |
| Morphine-N-oxide .....  | 9307      | I        |
| Normorphine .....   | 9313      | I        |
| Tilidine .....  | 9750      | I        |
| Alpha-methylfentanyl .....  | 9814      | I        |
| Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ..... | 9821      | I        |
| Methamphetamine .....   | 1105      | II       |
| Phenmetrazine .....   | 1631      | II       |
| Methylphenidate .....   | 1724      | II       |
| Amobarbital .....   | 2125      | II       |
| Pentobarbital .....   | 2270      | II       |
| Secobarbital .....  | 2315      | II       |
| Glutethimide .....  | 2550      | II       |
| Phencyclidine .....   | 7471      | II       |
| Phenylacetone .....   | 8501      | II       |
| Codeine .....   | 9050      | II       |
| Dihydrocodeine .....  | 9120      | II       |
| Diphenoxylate .....   | 9170      | II       |
| Ecgonine .....  | 9180      | II       |
| Ethylmorphine .....   | 9190      | II       |
| Hydrocodone .....   | 9193      | II       |
| Levorphanol .....   | 9220      | II       |
| Meperidine .....  | 9230      | II       |
| Meperidine intermediate-B .....   | 9233      | II       |
| Meperidine intermediate-C .....   | 9234      | II       |
| Dextropropoxyphene, bulk (non-dosage forms) .....                       | 9273      | II       |
| 14-Hydroxymorphone .....  | 9665      | II       |
| Noroxymorphone .....  | 9668      | II       |
| Sufentanil .....  | 9740      | II       |
| Fentanyl .....  | 9801      | II       |

The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis. In reference to drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols) the company plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinols. No other activities for these drug codes are authorized for this registration.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2020-08328 Filed 4-17-20; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-621]

#### **Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Groff NA Hemplex LLC**

**ACTION:** Notice of application.

**SUMMARY:** The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other

pending applications according to proposed regulations that, if finalized, would govern the program of growing marihuana for scientific and medical research under DEA registration.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefor, may file written comments on or objections to the issuance of the proposed registration on or before June 19, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW 8701 Morrisette Drive, Springfield, Virginia 22152. To ensure proper handling of comments, please reference Docket No. DEA-621 in all correspondence, including attachments.

**SUPPLEMENTARY INFORMATION:** The Controlled Substances Act (CSA) prohibits the cultivation and distribution of marihuana except by persons who are registered under the CSA to do so for lawful purposes. In accordance with the purposes specified in 21 CFR 1301.33(a), DEA is providing notice that the entity identified below has applied for registration as a bulk manufacturer of schedule I controlled substances. In response, registered bulk manufacturers of the affected basic class(es), and applicants therefor, may file written comments on or objections

of the requested registration, as provided in this notice. This notice does not constitute any evaluation or determination of the merits of the application submitted.

The applicant plans to manufacture bulk active pharmaceutical ingredients (APIs) for product development and distribution to DEA-registered researchers. If the application for registration is granted, the registrant would not be authorized to conduct other activity under this registration aside from those coincident activities specifically authorized by DEA regulations. DEA will evaluate the application for registration as a bulk manufacturer for compliance with all applicable laws, treaties, and regulations and to ensure adequate safeguards against diversion are in place.

As this applicant has applied to become registered as a bulk manufacturer of marihuana, the application will be evaluated under the criteria of 21 U.S.C. 823(a). DEA proposes to conduct this evaluation in the manner described in the rule proposed at 85 FR 16292, published on March 23, 2020, if finalized.

In accordance with 21 CFR 1301.33(a), DEA is providing notice that on February 28, 2020, Groff NA Hemplex LLC, 100 Redco Avenue, Suite